Hsbc Holdings PLC Boosts Stake in Kenvue Inc. $KVUE

Hsbc Holdings PLC boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 34.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,544,394 shares of the company’s stock after acquiring an additional 1,926,217 shares during the quarter. Hsbc Holdings PLC’s holdings in Kenvue were worth $143,893,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Ancora Advisors LLC acquired a new stake in Kenvue in the second quarter valued at $313,000. Canada Pension Plan Investment Board acquired a new position in shares of Kenvue during the 2nd quarter worth $74,895,000. Kapitalo Investimentos Ltda acquired a new position in shares of Kenvue during the 2nd quarter worth $1,108,000. Kinloch Capital LLC purchased a new position in shares of Kenvue in the 2nd quarter valued at about $4,265,000. Finally, Royal Capital Wealth Management LLC purchased a new position in shares of Kenvue in the 2nd quarter valued at about $311,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.4%

NYSE:KVUE opened at $19.34 on Wednesday. The company has a market capitalization of $37.16 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.40. The stock has a fifty day simple moving average of $19.10 and a 200-day simple moving average of $18.22.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same period in the previous year, the company posted $0.29 earnings per share. Kenvue’s revenue was up 3.0% on a year-over-year basis. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Analyst Ratings Changes

Several analysts recently commented on the stock. UBS Group reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.